Clinical researchers published new findings on psilocybin-assisted therapy for anorexia nervosa. An NHS hospital moved psychedelic treatment research closer to conventional healthcare. Oregonâs regulated psilocybin industry confronted a potentially significant increase in licensing costs, while a new grassroots organization in Ohio began advocating for the decriminalization of naturally occurring psychedelic plants and fungi. Outside psychedelic medicine, glowing mushrooms in Mexico captured widespread attention, underground fungi demonstrated their importance to island restoration, and mycologists prepared to gather in Portland for one of the fieldâs most important annual scientific meetings. Not every fungal story circulating this week represented research that was published during the past seven days. Some were newly released studies, while others were older findings receiving renewed media attention. That distinction matters, particularly in a field where exciting mushroom headlines can sometimes travel faster than the underlying science. Here are the most important mushroom developments from the past week.
Psilocybin therapy showed preliminary potential for anorexia nervosa
One of the weekâs most consequential mushroom-related developments came from Imperial College London researchers studying psilocybin-assisted therapy in women with anorexia nervosa. The pilot study, published in The British Journal of Psychiatry, included 21 adult women who had lived with anorexia nervosa for several years and had not achieved lasting remission through previous treatments. Participants completed three psilocybin dosing sessions over six weeks, receiving doses of 1 milligram, 25 milligrams, and 25 milligrams in a fixed sequence. The dosing sessions were combined with psychological preparation, therapeutic support, and follow-up care. Researchers reported statistically significant improvements in eating-disorder symptoms and motivation to change during follow-up. However, the degree of improvement varied considerably between participants, and not every participant maintained the same level of benefit over time. The study also requires careful interpretation. It was a small pilot project without a conventional control group, meaning it cannot establish that psilocybin caused the reported improvements. Participants knew they would receive psilocybin, and some could feel psychoactive effects even from the low initial dose, making effective blinding difficult. Headache, nausea, and dizziness were the most commonly reported adverse effects. The study also recorded two serious adverse events involving suicide attempts by one participant during the period between six and twelve months after treatment. Researchers concluded that larger and more rigorously controlled studies are necessary before psilocybin therapy can be considered an established treatment for anorexia nervosa. The significance of the research is not that psilocybin has been proven to treat anorexia. It has not. The importance is that researchers are investigating whether psychedelic therapy could help address the cognitive rigidity, fear, identity attachment, and resistance to change that can make long-term anorexia especially difficult to treat. The pilot provides enough evidence to justify additional research, but not enough to support unsupervised use or broad clinical claims.
Psilocybin research moved further inside the NHS
Another major development came from the United Kingdom, where an NHS hospital in Doncaster is participating in a clinical trial involving psilocybin for severe, treatment-resistant depression. The project is being conducted through a collaboration between the NHS and private clinical research organization Clerkenwell Health. Participants receive psilocybin under controlled hospital conditions with support from trained therapists, nurses, and clinical personnel. This represents more than another psychedelic clinical trial. Conducting the research within an NHS hospital allows healthcare professionals to develop direct experience with patient screening, psychedelic dosing sessions, psychological support, emergency procedures, and post-session monitoring. That infrastructure could become increasingly important if a psilocybin-based treatment eventually receives regulatory approval. The practical challenge surrounding psychedelic medicine has never been limited to proving that a compound can produce a clinical effect. Healthcare systems must also determine who should receive treatment, who should not receive it, how sessions should be supervised, how facilitators should be trained, and how patients should be monitored afterward. Research conducted within existing healthcare institutions may help answer those implementation questions.
Oregonâs psilocybin program faced proposed fee increases
Oregonâs regulated psilocybin system entered another difficult stage this week when proposed licensing increases raised concerns among service-center operators and manufacturers. Under the Oregon Health Authority proposal, annual licensing fees for psilocybin service centers and manufacturers would increase from $10,000 to $20,000 beginning next year. State officials say the increases are needed because slower-than-expected industry growth and higher operating expenses have created a funding shortfall within the program. Oregonâs system is primarily funded through fees paid by the businesses and professionals participating in it. When fewer businesses enter or remain in the market, the cost of maintaining regulatory oversight is distributed across a smaller number of license holders. That creates a difficult cycle. High operating costs can discourage new businesses from entering the market. A smaller market produces less licensing revenue. Regulators then consider raising fees, which can place additional pressure on the businesses that remain. Oregon voters approved Measure 109 in 2020, creating the first state-regulated system in the United States through which adults can legally receive supervised psilocybin services at licensed facilities. The program does not operate like a recreational dispensary market. Clients consume psilocybin at licensed service centers under supervision rather than purchasing mushrooms to take home. The current debate shows that changing the law is only the beginning. A regulated psychedelic program must also attract enough clients, facilitators, manufacturers, and service centers to support itself financially. If licensing costs continue rising while consumer participation remains limited, Oregon could lose some of the businesses needed to keep the system accessible.
Grassroots mushroom decriminalization organizing reached Toledo
The movement to change local psychedelic policy also gained a new participant this week with the launch of Decrim Nature Toledo. The grassroots organization is advocating for the removal of criminal penalties associated with the personal possession and cultivation of naturally occurring entheogenic plants and fungi. The group held a public event in Toledo on July 8 as it began building local support and community awareness. Local decriminalization efforts are different from regulated therapeutic programs like Oregonâs. A regulated model establishes licensed producers, facilitators, testing requirements, service locations, and administrative fees. A decriminalization model generally seeks to make personal possession, cultivation, or sharing a lower law-enforcement priority or remove certain local penalties. That distinction is becoming increasingly important as psychedelic policy develops across the United States. Some advocates favor tightly controlled medical access. Others argue that naturally occurring fungi should not be restricted exclusively to expensive clinical or commercial systems. The launch of another local campaign demonstrates that psychedelic mushroom policy remains active at the municipal level, even as state and federal officials debate broader therapeutic frameworks.
Glowing mushrooms in Mexico returned to the spotlight
One of the weekâs most visually striking stories involved bioluminescent fungi growing in Mexicoâs cloud forests. New media coverage highlighted research documenting glowing fungi in protected forests in western Mexico, including previously undescribed species associated with the genus Mycena. Researchers used morphological examination and genetic analysis to help distinguish the specimens. These mushrooms produce a faint green light through a biochemical reaction involving fungal luciferin and enzymes associated with light production. The process releases visible light with very little heat, producing the cold glow associated with bioluminescent organisms. Approximately 80 mushroom-forming fungal species are currently known to display some form of bioluminescence, although the trait may occur in the fruiting body, the mycelium, or both depending on the species. Scientists are still debating why fungal bioluminescence evolved. One leading explanation is that the light attracts insects and other small animals that can transport spores. Experiments involving illuminated mushroom models have produced some evidence for this theory, but other studies have not found a clear relationship between glowing fruiting bodies and insect visitation. The ecological function may therefore differ among fungal species. The underlying discoveries were not all made during this week. The new development was the renewed public attention surrounding the findings. Even so, the story carries an important conservation message. Cloud forests are exceptionally rich habitats that can contain fungi unknown to science. Habitat loss can erase those organisms before researchers have an opportunity to document them, sequence them, or understand their ecological roles.
Underground fungi may determine whether island forests recover
Another ecological study that returned to the news cycle this week examined the hidden fungal relationships supporting Palmyra Atoll, a remote group of islands in the Pacific Ocean. The underlying research was published earlier in 2026, but renewed coverage emphasized its broader implications for ecological restoration. Researchers found that native Pisonia grandis trees on Palmyra were closely associated with ectomycorrhizal fungi from the genus Tomentella. Every Pisonia root sampled by the research team contained these fungal partners. The fungi help the trees obtain nutrients from an unusual island environment heavily influenced by seabird guano. The trees provide nesting habitat for seabirds, while nutrients deposited by those birds support the forest and eventually move into surrounding marine ecosystems.
This creates a connected ecological chain:
Fungi support the trees. The trees support seabirds. The seabirds deliver nutrients that influence the forest and nearby coral reefs. Restoration teams had already removed approximately 1.5 million invasive coconut palms from Palmyra by 2022. However, researchers found that the fungal partners associated with Pisonia became less common farther away from surviving native trees. Simply removing invasive vegetation may therefore be insufficient if the fungi required by native seedlings are no longer present in the soil. Future restoration projects may need to consider fungal inoculation or soil transplantation alongside conventional tree planting. The research reinforces a lesson that is becoming increasingly difficult for conservation organizations to ignore: restoring plants without restoring their microbial and fungal partners can leave an ecosystem incomplete.
The Mycological Society of America prepared for its annual meeting
The professional mycology community also prepared for an important week ahead. The Mycological Society of Americaâs 2026 annual meeting is scheduled for July 11 through July 15 in Portland, Oregon. This yearâs theme is âBridging Mycology Across Communities and Disciplines.â The meeting is expected to bring together researchers, students, educators, field mycologists, and other fungal specialists for scientific presentations, poster sessions, networking, and organized fungal activities. The theme reflects a broader transformation occurring throughout mycology. Fungal research is no longer confined to taxonomy or forest identification. Modern mycology intersects with medicine, agriculture, biotechnology, climate science, conservation, materials engineering, food production, mental health, and community science. Creating stronger connections among those fields could help prevent valuable research from remaining isolated inside specialized journals or institutions.
What this weekâs mushroom news tells us
The most important theme of this week was not any single mushroom species or research result. It was infrastructure. Psilocybin researchers are trying to build the evidence needed for responsible medical use. Hospitals are beginning to build systems capable of supporting psychedelic clinical trials. Oregon is struggling to build a financially sustainable regulated market. Local organizers are building political support for decriminalization. Conservationists are learning that rebuilding forests may require rebuilding fungal networks beneath them. The mushroom movement is becoming more established, but establishment creates new responsibilities. Clinical claims must be supported by credible evidence. Psychedelic programs must remain accessible without sacrificing safety. Conservation plans must include fungi rather than treating them as an afterthought. Communities must be able to discuss controversial subjects without misinformation, censorship, or reckless promotion. That is also why dedicated mushroom communities matter. MycoHub gives cultivators, researchers, foragers, educators, businesses, and mushroom enthusiasts a focused place to follow developments, exchange knowledge, and discuss the rapidly changing fungal world without depending entirely on scattered social feeds. As mycology expands across science, culture, medicine, and environmental policy, keeping the community connected may be just as important as keeping it informed.
Sources and further reading
- The British Journal of Psychiatry: Psilocybin therapy for adult females with anorexia nervosa
- Imperial College London and Medical Xpress coverage of the anorexia nervosa pilot study
* Financial Times: Inside the NHS hospital trialling psychedelics to treat depression
* Jefferson Public Radio: Oregon proposes steep psilocybin licensing fee increases
- The Blade: New local group seeks decriminalization of psychedelic plants and fungi
Discussion
Share questions, reactions, and context with the community.